Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 6Terminated 2Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Lymphoid 2Plasma cell 1

Conditions

Multiple Myeloma 112Recurrence 29Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Neoplasms 14Neoplasms, Plasma Cell 13Leukemia 10Lymphoma, Non-Hodgkin 8Lymphoma 8Leukemia, Myeloid, Acute 8Carcinoma, Non-Small-Cell Lung 8Lymphoma, Large B-Cell, Diffuse 7Burkitt Lymphoma 7Vomiting 6Prostatic Neoplasms 6Breast Neoplasms 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasm Metastasis 5Nausea 5Lung Neoplasms 5Pancreatic Neoplasms 3Lymphoma, Follicular 3Immunoglobulin Light-chain Amyloidosis 3Hematologic Neoplasms 3Hematologic Diseases 3Glioblastoma 3Amyloidosis 3Smoldering Multiple Myeloma 2Renal Insufficiency 2Oligodendroglioma 2Myelodysplastic Syndromes 2

Interventions

Cyclophosphamide 39fludarabine phosphate 36Azacitidine 32fludarabine 24Whole-Body Irradiation 22Busulfan 22Tacrolimus 21Antilymphocyte Serum 21Mycophenolic Acid 19Filgrastim 17Methotrexate 16Melphalan 15Peripheral Blood Stem Cell Transplantation 13venetoclax 12thymoglobulin 12Granulocyte Colony-Stimulating Factor 12Cytarabine 12Cyclosporine 12Thiotepa 9Cord Blood Stem Cell Transplantation 9Alemtuzumab 8Rituximab 7Radiotherapy 7Methylprednisolone 7Decitabine 7Clofarabine 7Lenalidomide 6Stem Cell Transplantation 5Sirolimus 5Nivolumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Myelodysplastic Syndromes × Dexamethasone × Clear all
NCT04752163 2025-05-23

DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Terminated
17 enrolled 15 charts
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03465540 2023-04-12

Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies

Amgen

Phase 1 Terminated
24 enrolled 21 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡